Navigation Links
New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease
Date:6/11/2009

global Phase 3 clinical trials in adults, with regulatory submissions expected in 2010.

Pneumococcal Disease

Pneumococcal disease is complex and describes a group of illnesses, all caused by the bacterium Streptococcus pneumoniae. Pneumococcal disease affects both children and adults, and includes invasive infections such as bacteremia/sepsis and meningitis, as well as pneumonia and otitis media (middle ear infection).

Most recently serotype 19A, which is included in the candidate vaccine, has been increasing in prevalence in many regions of the world and is frequently resistant to antibiotics.

Indication for Prevenar

Prevenar is indicated for active immunization against disease by Streptococcus pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F and 23F (including sepsis, meningitis, pneumonia, bacteremia, and acute otitis media) in infants and children from 2 months up to 5 years of age.

Important Safety Information for Prevenar

In clinical studies (n=18,168), the most frequently reported adverse events included injection site reactions, fever (greater than or equal to 38 degrees C/100.4 degrees F), irritability, drowsiness, restless sleep, decreased appetite, vomiting, diarrhea, and rash.

Risks are associated with all vaccines, including Prevenar. Hypersensitivity to any vaccine component, including diphtheria toxoid, is a contraindication to its use. Prevenar does not provide 100% protection against vaccine serotypes or protect against non vaccine serotypes. The decision to administer Prevenar should be based on its efficacy in preventing invasive pneumococcal disease (IPD).

About Wyeth Pharmaceuticals

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervou
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
6. Phase III Trial Finds Pharmaxis Bronchitol Effective
7. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
8. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
9. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
10. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
11. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... (PRWEB) April 21, 2015 Contract Research Organization ... plans to relocate into a new 41,500 ft2 facility. ... headquarters, currently located at 16825 W. 116th St. in Lenexa, ... half times the customized laboratory space, will remain in the ... company was founded more than twenty years ago. Remaining ...
(Date:4/21/2015)... 2015 AbilTo, Inc., the nation,s leading digital ... has been accepted as a presentation to be included ... place on June 5-6, 2015 in Boston, Massachusetts ... Diabetes Association, the cost of diabetes to the American ... result of increased inpatient, outpatient, and pharmacy costs, the ...
(Date:4/21/2015)... 2015 Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) ... on Thursday, April 23, 4:30 p.m. ET. Participants are ... Investor call information: U.S./ ... toll number: (925) 418-7845 Participant Passcode: 32888538 ... Amirkiai , tina.amirkiai@fleishman.com . Access will ...
(Date:4/21/2015)... , April 21, 2015  Tute Genomics, a leading ... of Josh Forsythe as VP of Marketing. Mr. ... witnessed a significant expansion in its commercial operations over the ... " Josh Forsythe is a tremendous addition ... MD MBA, CEO of Tute Genomics. "Josh,s vast experience commercializing ...
Breaking Biology Technology:XenoTech Plans Expansion to New Global Headquarters after Impressive Revenue Growth in 2014 2XenoTech Plans Expansion to New Global Headquarters after Impressive Revenue Growth in 2014 3AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 2AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 3Ampio Announces Investor Call on Thursday, April 23, 4:30 p.m. ET 2Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 2Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 3Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 4
... ... Position in Automated QT Studies , ... Rochester, New York (PRWEB) October 8, 2009 -- iCardiac Technologies, Inc., ... that an international pharmaceutical company has awarded iCardiac a comprehensive cardiac safety study. ...
... ... Obama , ... Ill. (Vocus) October 7, 2009 -- The IBM Blue Gene series of energy-efficient supercomputers, ... Barack Obama as a Medal of Technology and Innovation award-winner on October 7 in ...
... NEW YORK, Oct. 7 NeoStem, Inc. (NYSE Amex: ... processing and long-term storage of adult stem cells for ... Securities and Exchange Commission has declared effective its Registration ... The Registration Statement, including the joint proxy statement, is ...
Cached Biology Technology:Global Pharmaceutical Company Awards Comprehensive Cardiac Safety Study to iCardiac 2DOE Labs Take Pride in Award-Winning IBM Blue Gene Series 2DOE Labs Take Pride in Award-Winning IBM Blue Gene Series 3DOE Labs Take Pride in Award-Winning IBM Blue Gene Series 4United States Securities and Exchange Commission Declares Effective Registration Statement for NeoStem's Acquisition of China Biopharmaceuticals Holdings, Inc. and a Controlling Interest in Leading Chinese Pharmaceutical Company; Meeting of Each Com 2United States Securities and Exchange Commission Declares Effective Registration Statement for NeoStem's Acquisition of China Biopharmaceuticals Holdings, Inc. and a Controlling Interest in Leading Chinese Pharmaceutical Company; Meeting of Each Com 3United States Securities and Exchange Commission Declares Effective Registration Statement for NeoStem's Acquisition of China Biopharmaceuticals Holdings, Inc. and a Controlling Interest in Leading Chinese Pharmaceutical Company; Meeting of Each Com 4
(Date:4/14/2015)... Conn. , April 14, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... been nominated for the 2015 New York Design Awards ... The Design100, New York City Design Awards are part ... based on over 2,500 ratings from the marketplace, industry ...
(Date:4/10/2015)... 2015 Research and Markets ( ... "Security Competitive Profiles - NEC" report to their ... NEC will continue to supply a range of IT ... a company focus on the development of a Big ... opportunities in the Asia-Pacific region ...
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. ... a biometric authentication company focused on the growing ... filed provisional patent 62/143028 for MINIATURE, ... ENERGY TRANSFER  NXT-ID introduces a new ... This patent surrounds the use of miniature antenna ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... to prevailing wisdom, a new study from plant biologists at ... indeed chaperone proteins across the membranes of chloroplasts, just as ... published online in the January issue of the journal ... tasks in a living cell is to move things across ...
... This release is available in Spanish . ... to ethnic minority groups receive worse health care in the ... world,s most developed countries. This conclusion emerges from a research ... most comprehensive bibliographic review worldwide to date on health care ...
... is impacted as much or more by environmental change ... Professor Caryn Vaughn, who serves as director of the ... extinct, we don,t necessarily think of the common species ... Vaughn. "We need to be concerned about these ...
Cached Biology News:Green plant transport mystery solved 2Poorer diabetics receive worse care than other in countries with universal health coverage 2Poorer diabetics receive worse care than other in countries with universal health coverage 3Environmental change impacts Oklahoma rivers 2
Bis-Acrylamide (bis) is a monomer used as a crosslinker with acrylamide to form polyacrylamide electrophoretic gels. This 2% bis solution is supplied as 500 ml....
... EnVision™ G|2 Doublestain System is a ... visualization kit. The kit is intended ... simultaneous detection of two different antigens ... compatible with suitably diluted rabbit and ...
AVOID FREEZE/THAW CYCLES. Recognizes the UCP-2 protein....
Rabbit Anti-Human Janus Kinase 2 (JAK2 Polyclonal Antibody Family: Protein Kinase Sub-Family: TYK2/JAK Applications: ELISA, Western Blot...
Biology Products: